{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-25-001126","form_type":"8-K","ticker":"CLDX","cik":"0000744218","company_name":"Celldex Therapeutics, Inc.","filed_at":"2025-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:06.253234+00:00","generated_at":"2026-05-26T02:51:34.373610+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Celldex reports Q4 2024 net loss of $47.1M; cash $725.3M; Phase 3 CSU studies enrolling","bullets":["Cash, equivalents and securities $725.3M at Dec 31, 2024; company funded through 2027.","Q4 2024 net loss $47.1M ($0.71/sh) vs $43.3M ($0.83/sh) Q4 2023; R&D expenses $46.9M.","Phase 3 CSU studies EMBARQ-CSU1/2 enrolling ~915 patients each across 40 countries.","Phase 3 CIndU program expected to start in 2025; Phase 2 EoE study fully accrued.","Phase 1 CDX-622 (SCF/TSLP bispecific) initiated; multiple data readouts expected in 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-25-001126","json":"https://secwatch.observer/filing/0001171843-25-001126.json","markdown":"https://secwatch.observer/filing/0001171843-25-001126.md","text":"https://secwatch.observer/filing/0001171843-25-001126.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/744218/000117184325001126/0001171843-25-001126-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/744218/000117184325001126/f8k_022725.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T02:51:34.373610+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}